The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly.
After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerability of this group of drugs when used in older people. This article reviews the pathophysiology of the condition, its effect on the elderly and the evidence for the use of extended release tolterodine in the elderly using data from placebo and active drug controlled studies.
Ulahannan
Danny
D
Department of Geriatric Medicine, University College Hospital, London, UK.
Wagg
Adrian
A
D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003408:Cresols / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000494:pharmacology; D010665:Phenylpropanolamine / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology
D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate